Mumbai, Feb. 27 -- Zydus Lifesciencesannounced that the pivotal Dahlia pharmacokinetic study (PK study) has successfully met its primary study objective. The randomized, double-blind, multi-centre clinical PK study demonstrated pharmacokinetic equivalence (bioequivalence) of FYB206 (pembrolizumab) with the oncology blockbuster drug Keytruda(R). Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda(R) (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets.

Published by HT Digital Content Services with permission from Capital Market....